SCHEMBL19976727

SCHEMBL19976727

CCC(C)N/C(=N/C(=O)c1ccc(F)c(F)c1)Nc1[nH]nc2cc(C(F)(F)F)ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.36
MAPK1 P28482 3/20 0.35
MAP2K4 P45985 2/20 0.35
MAPK6 Q16659 2/20 0.35
MAPKAPK5 Q8IW41 1/20 0.35
TRPA1 O75762 3/20 0.35
PDE2A O00408 1/20 0.34
MAPKAPK3 Q16644 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PTGER4 P35408 2/20 0.33
GPR139 Q6DWJ6 1/20 0.33
PTGFR P43088 1/20 0.33
CACNA1H O95180 1/20 0.32
PTGES O14684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19976728 0.93 PTGES (0.37) GSK3BMAPK1MAP2K4MAPK6MAPKAPK5
SCHEMBL19976944 0.91 MAPK1 (0.36) GSK3BMAPK1MAP2K4MAPK6MAPKAPK5
SCHEMBL19976851 0.84 POLB (0.35) MAPK1MAP2K4MAPK6TRPA1PDE2A
SCHEMBL19976798 0.84 PTGES (0.36) MAPK1LMNATP53MAPTMEN1
SCHEMBL19976928 0.82 CTNNB1 (0.37) MAPK1LMNATP53HTTKMT2A
SCHEMBL19976784 0.80 MAPK1 (0.38) MAPK1MAP2K4
SCHEMBL19976777 0.78 POLB (0.39) MAPK1LMNAMEN1KMT2A
SCHEMBL16752811 0.76 GSK3B (0.48) GSK3BMAPK1MAP2K4MAPK6MAPKAPK5
SCHEMBL16752808 0.76 GSK3B (0.48) GSK3BMAPK1MAP2K4MAPK6MAPKAPK5
SCHEMBL16752809 0.76 GSK3B (0.48) GSK3BMAPK1MAP2K4MAPK6MAPKAPK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920012-B2 Indazole guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-03-20 US disclosed